Medication firm Glenmark Pharmaceuticals on Saturday said it has propelled antiviral medication Favipiravir, under the brand name FabiFlu, for the treatment of patients with gentle to moderate Covid-19 at a cost of about Rs 103 for every tablet.
The medication will be accessible as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a portion of 34 tablets, Glenmark Pharmaceuticals said.
FabiFlu is the first oral favipiravir-endorsed drug in Quite a while for the treatment of Covid-19, it included.
It is a solution based prescription, with a suggested portion being 1,800 mg twice day by day on the very first moment, trailed by 800 mg twice day by day up to day 14, the medication firm said.
The organization is creating the active pharmaceutical ingredients (API) for the item at its Ankleshwar plant, while the definition is being produced at its Baddi plant.
The medication will be accessible both through emergency clinics and the retail channel, Glenmark said.
“We chose to initiate work on Favipiravir, as it has proven in-vitro activity against SARS CoV2 virus, which is the virus responsible for Covid-19.
“Second is it has a wide therapeutic safety margin for Covid-19 at the dose that we administer,” Glenmark Pharmaceuticals President India Formulations, Middle East and Africa Sujesh Vasudevan said at an online press conference.
